

Table e-2. Ocrelizumab induced changes in cytokine producing cells (n=53).

	<i>Absolute numbers (cells/μL)</i>			<i>Percentages [Subset]</i>		
	0M	6M	<i>p</i>	0M	6M	<i>p</i>
CD19						
TNF α [CD19]	58 (35-99)	0.3 (0.1-1.5)	<0.0001	24.5 (15.7-35.3)	8.3 (4.6-14.5)	<0.0001
GM-CSF [CD19]	28 (13-46)	0.7 (0.3-4.2)	<0.0001	11.2 (8.5-14.9)	22.5 (12.5-31.7)	<0.0001
IL-6 [CD19]	31 (13-46)	1.3 (0.2-5.3)	<0.0001	14.7 (8.8-20.9)	20.0 (12.5-30.9)	0.004
IL-10 [CD19]	15 (10-31)	1.0 (0.3-4.8)	<0.0001	6.6 (4.1-10.8)	15.8 (9.7-32.1)	<0.0001
CD4						
IL-10 [CD4]	15 (8.7-21)	17 (11-26)	<i>ns</i>	1.2 (0.9-1.6)	1.3 (0.8-1.7)	<i>ns</i>
GM-CSF [CD4]	105 (67-145)	117 (84-153)	<i>ns</i>	8.8 (7.0-11.5)	8.6 (7.3-10.5)	<i>ns</i>
TNF α [CD4]	509 (349-748)	545 (382-779)	<i>ns</i>	46.6 (32.9-56.0)	41.0 (33.7-50.7)	<i>ns</i>
IL-17 [CD4]	13 (8.7-18)	16 (10-34)	<i>ns</i>	1.0 (0.7-1.6)	1.4 (0.9-2.2)	<i>ns</i>
IFN γ [CD4]	101 (54-145)	87 (49-131)	<i>ns</i>	9.1 (5.1-11.7)	7.3 (3.3-9.6)	0.03
CD8						
IL-10 [CD8]	9.5 (4.0-16)	11 (6.5-16)	<i>ns</i>	3.6 (2.1-5.5)	4.8 (2.8-6.7)	<i>ns</i>
GM-CSF [CD8]	38 (19-61)	36 (20-62)	<i>ns</i>	13.1 (9.7-16.9)	13.8 (11.1-19.3)	<i>ns</i>
TNF α [CD8]	140 (92-199)	109 (61-187)	<i>ns</i>	53.1 (41.0-61.3)	44.5 (32.8-55.5)	<i>ns</i>
IL-17 [CD8]	7.8 (4.1-14)	10 (6.0-18)	<i>ns</i>	3.1 (2.0-4.6)	3.9 (2.6-6.6)	<i>ns</i>
IFN γ [CD8]	106 (48-154)	66 (32-130)	<i>ns</i>	36.5 (27.3-50.0)	26.3 (18.0-40.7)	0.004
CD14						
IL-1 β [CD14]	75 (24-137)	104 (50-142)	<i>ns</i>	61.9 (47.3-79.2)	63.2 (51.3-80.2)	<i>ns</i>
IL-10 [CD14]	8.7 (4.9-19)	15 (6.5-23)	<i>ns</i>	8.9 (4.3-21.7)	11.7 (5.3-17.4)	<i>ns</i>
TNF α [CD14]	99 (37-179)	114 (68-202)	<i>ns</i>	81.2 (70.7-87.2)	83.2 (74.0-89.1)	<i>ns</i>
IL-12 [CD14]	13 (5.5-30)	18 (6.6-41)	<i>ns</i>	15.6 (7.7-26.0)	14.4 (9.0-25.0)	<i>ns</i>
IL-6 [CD14]	30 (14-62)	37 (21-64)	<i>ns</i>	33.8 (19.2-45.0)	28.0 (18.9-42.8)	<i>ns</i>

Footnote: Results are shown as Median (25-75% IQR). Absolute numbers are displayed as cells/ μ L.

Percentages are referred to the subset included into square brackets []. P values were corrected by using

Bonferroni test. 0M, 0 Months (pre-ocrelizumab treatment); 6M, 6 Months of ocrelizumab treatment; GM-CSF,

Granulocyte-Macrophage Colony-Stimulating Factor; IFN γ , Interferon gamma; IL, interleukin; ns, non-significant; TNF α , Tumor Necrosis Factor-alpha.